Frequent alterations of homologous recombination repair pathway in primary and chemotolerant breast carcinomas: clinical importance
- PMID: 27646721
- DOI: 10.2217/fon-2016-0289
Frequent alterations of homologous recombination repair pathway in primary and chemotolerant breast carcinomas: clinical importance
Abstract
Aim: To understand the importance of homologous recombination repair pathway in development of breast carcinoma (BC), alterations of some key regulatory genes like BRCA1, BRCA2, FANCC and FANCD2 were analyzed in pretherapeutic/neoadjuvant chemotherapy (NACT)-treated BC samples.
Materials & methods: Alterations (deletion/methylation/expression) of the genes were analyzed in 118 pretherapeutic and 41 NACT-treated BC samples.
Results: High deletion/methylation (29-68%) and 64-78% overall alterations of the genes were found in the samples. Concordance was evident between alteration and protein expression of the genes. Estrogen/progesterone receptor-negative tumors showed significantly high alterations even in NACT-treated samples having low CD44 and proliferating cell nuclear antigen expression. Pretherapeutic patients with alterations showed poor prognosis.
Conclusion: Alterations of homologous recombination repair pathway genes are needed for the development of BC.
Keywords: HRR pathway; breast carcinoma; neoadjuvant chemotherapy.
Similar articles
-
Induction of HRR genes and inhibition of DNMT1 is associated with anthracycline anti-tumor antibiotic-tolerant breast carcinoma cells.Mol Cell Biochem. 2019 Mar;453(1-2):163-178. doi: 10.1007/s11010-018-3442-5. Epub 2018 Sep 3. Mol Cell Biochem. 2019. PMID: 30178275
-
Hypomethylation of mismatch repair genes MLH1 and MSH2 is associated with chemotolerance of breast carcinoma: Clinical significance.J Surg Oncol. 2019 Jan;119(1):88-100. doi: 10.1002/jso.25304. Epub 2018 Nov 27. J Surg Oncol. 2019. PMID: 30481381
-
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.Breast Cancer Res. 2014 Dec 5;16(6):475. doi: 10.1186/s13058-014-0475-x. Breast Cancer Res. 2014. PMID: 25475740 Free PMC article.
-
Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.Breast Cancer Res Treat. 2015 Oct;153(3):493-505. doi: 10.1007/s10549-015-3578-x. Epub 2015 Sep 23. Breast Cancer Res Treat. 2015. PMID: 26400847 Review.
-
Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.Drug Des Devel Ther. 2015 Sep 18;9:5277-85. doi: 10.2147/DDDT.S86929. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26425077 Free PMC article. Review.
Cited by
-
Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors.Front Oncol. 2022 Jun 17;12:880643. doi: 10.3389/fonc.2022.880643. eCollection 2022. Front Oncol. 2022. PMID: 35785170 Free PMC article. Review.
-
Induction of HRR genes and inhibition of DNMT1 is associated with anthracycline anti-tumor antibiotic-tolerant breast carcinoma cells.Mol Cell Biochem. 2019 Mar;453(1-2):163-178. doi: 10.1007/s11010-018-3442-5. Epub 2018 Sep 3. Mol Cell Biochem. 2019. PMID: 30178275
-
BRCA1 promoter methylation & its immunohistochemical correlation in sporadic breast cancer.Indian J Med Res. 2023 Jan;158(1):47-54. doi: 10.4103/ijmr.IJMR_4605_20. Indian J Med Res. 2023. PMID: 37602586 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous